The National Board of Early Access Medicine (NBEAM) serves physicians and therapeutics companies with education and policy support on the use of Expanded Access clinical trials.
A 501c3 non-profit corporation, founded in 2012 under its original name, ALS Emergency Treatment Fund. NBEAM is the oldest continuously running organization that specializes in pre-first-approval access to new medicines.
Company Details
- Employees
- 1
- Founded
- 2012
- Address
- Bay Area, San Francisco,ca,united States
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- alsetf.org
- Keywords
- Expanded Access Programs, Clinical Development, Amyotrophic Lateral Sclerosis, Regulatory Affairs.
- HQ
- San Francisco, CA
National Board Of Early Access Medicine Questions
National Board Of Early Access Medicine's website is alsetf.org
National Board Of Early Access Medicine's LinkedIn profile is https://www.linkedin.com/company/expandedaccess
National Board Of Early Access Medicine has
1 employees.
View email and phone details for 1
employees at National Board Of Early Access Medicine.
National Board Of Early Access Medicine's industry is
Pharmaceutical Manufacturing
National Board Of Early Access Medicine's top competitors are
Joe Boorady, Llc,
Ncs Pharmaceuticals,
National Pharmaceutical Returns, Inc.,
Elio Health,
Neosinus Health,
Navaxxess Health Solutions, Llc,
Nangiotx,
Natural Therapeutics Inc,
Adora Life Science,
Natural Kneads.
National Board Of Early Access Medicine's categories are Pharmaceutical Manufacturing
National Board Of Early Access Medicine's founding year is 2012
